公开(公告)号：AU2016311429A1

公开(公告)日：2018-04-19

申请号：AU2016311429

申请日：2016-08-25

Applicant: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES

Inventor： LIU SHI-HUI ,  LEPPLA STEPHEN H ,  BUGGE THOMAS H ,  WEIN ALEXANDER N ,  PETERS DIANE E ,  LIU JIE ,  CHEN KUANG-HUA

IPC: C07K14/325 ,  A61K39/07

Abstract: Disclosed is a

公开(公告)号：AU2015369712A1

公开(公告)日：2017-07-20

申请号：AU2015369712

申请日：2015-12-22

Applicant: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES ,  UNIV NORTH CAROLINA CHAPEL HILL

Inventor： BOXER MATTHEW BRIAN ,  ROHDE JASON MATTHEW ,  PRAGANI RAJAN ,  LIU LI ,  DAVIS MINDY IRENE EMILY ,  BRIMACOMBE KYLE RYAN ,  SHEN MIN ,  SIMEONOV ANTON ,  KARAVADHI SURENDRA ,  URBAN DANIEL JASON ,  JADHAV AJIT ,  WANG XIAODONG ,  MCIVER ANDREW LOUIS

IPC: C07D215/22 ,  A61K31/4436 ,  A61K31/4545 ,  A61K31/4704 ,  A61K31/4725 ,  A61K31/5377 ,  A61K31/55 ,  A61P35/00 ,  C07D401/04 ,  C07D417/04 ,  C07D417/14 ,  C07D471/04

Abstract: Compounds of Formula I and Formula II and the pharmaceutically acceptable salts thereof are disclosed The variables A, B, Y, Z, X

公开(公告)号：AU2013271378A1

公开(公告)日：2014-12-18

申请号：AU2013271378

申请日：2013-06-07

Applicant: BETH ISRAEL DEACONESS MEDICAL CT INC ,  THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES

Inventor： LU KUN PING ,  BOXER MATTHEW BRIAN ,  DAVIS MINDY IRENE EMILY ,  PRAGANI RAJAN ,  SHEN MIN ,  SIMEONOV ANTON MOMTCHILOV ,  WEI SHUO ,  ZHOU XIAO ZHEN

IPC: A61K31/473 ,  C12N9/90

Abstract: The invention features compositions and methods for inhibiting the Pin1 protein, and the treatment of disorders characterized by elevated Pin1 levels.

公开(公告)号：AU2018251788B2

公开(公告)日：2025-04-10

申请号：AU2018251788

申请日：2018-04-11

Applicant: AURA BIOSCIENCES INC ,  THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES

Inventor： DE LOS PINOS ELISABET ,  SCHILLER JOHN TODD ,  KINES RHONDA C

IPC: A61K38/16 ,  A61K39/12 ,  A61K39/39 ,  A61K39/395 ,  A61K41/00 ,  A61K47/42 ,  A61K47/64 ,  B82Y5/00

Abstract: Some embodiments of the present disclosure are directed to methods and compositions for the treatment of tumors, using a combination of immunotherapeutic agents and tumor-targeting viral capsid protein assemblages comprising anti-cancer molecules conjugated to viral capsid proteins.

公开(公告)号：SMT202400465T1

公开(公告)日：2025-01-14

申请号：SMT202400465

申请日：2015-02-04

Applicant: KITE PHARMA INC ,  THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES

Inventor： ROSENBERG STEVEN A ,  BETTER MARC ,  FELDMAN STEVEN A

公开(公告)号：AU2021215132A1

公开(公告)日：2021-09-02

申请号：AU2021215132

申请日：2021-08-10

Applicant: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES

Inventor： MYLES IAN ANTHENI ,  DATTA SANDIP K

IPC: A61K9/00 ,  A61K9/06 ,  A61K35/74

Abstract: Pharmaceutical compositions are disclosed that includes a therapeutically effective amount of a purified viable gram negative bacteria and a pharmaceutically acceptable carrier. The pharmaceutical compositions are formulated for topical administration. Methods of treating atopic dermatitis using these pharmaceutical compositions are also disclosed.

公开(公告)号：AU2015269219B2

公开(公告)日：2020-12-24

申请号：AU2015269219

申请日：2015-06-05

Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER ,  THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES

Inventor： ADUSUMILLI PRASAD S ,  SADELAIN MICHEL ,  DIMITROV DIMITER S ,  FENG YANG

IPC: A61K39/00

Abstract: The presently disclosed subject matter provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to chimeric antigen receptors (CARs) that specifically target human mesothelin, and immunoresponsive cells comprising such CARs. The presently disclosed mesothelin-targeted CARs have enhanced immune-activating properties, including anti-tumor activity.

公开(公告)号：AU2014273917B2

公开(公告)日：2020-07-02

申请号：AU2014273917

申请日：2014-06-02

Applicant: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES

Inventor： JOHNSON JEFFREY A ,  HENEINE WALID M ,  LIPSCOMB JONATHAN T ,  WEI XIERONG

IPC: C12Q1/70

Abstract: Disclosed are compositions including primers and probes, which are capable of interacting with the disclosed nucleic acids, such as the nucleic acids encoding the reverse transcriptase, protease, or integrase of HIV as disclosed herein. Thus, provided is an oligonucleotide comprising any one of the nucleotide sequences set for in SEQ ID NOS: 1-89, 96-122, and 124-151. Also provided are the oligonucleotides consisting of the nucleotides as set forth in SEQ ID NOS: 1-89, 96-122, and 124-151. Each of the disclosed oligonucleotides is a probe or a primer. Also provided are mixtures of primers and probes and for use in RT-PCR and primary PCR reactions disclosed herein. Provided are methods for the specific detection of several mutations in HIV simultaneously or sequentially. Mutations in the reverse transcriptase, protease, or integrase of HIV can be detected using the methods described herein.

公开(公告)号：RS60270B1

公开(公告)日：2020-06-30

申请号：RSP20200525

申请日：2016-03-18

Applicant: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES

Inventor： CONNORS MARK ,  HUANG JINGHE ,  KANG BYONG HA ,  MASCOLA JOHN ,  ISHIDA ELISE ,  ZHOU TONGQING ,  KWONG PETER ,  ZHENG ANQI

IPC: C07K16/10 ,  A61P31/18

公开(公告)号：AU2018212002A1

公开(公告)日：2019-08-29

申请号：AU2018212002

申请日：2018-01-30

Applicant: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES

Inventor： CHOU JANICE J

IPC: C12N15/86 ,  A61K38/45 ,  A61K48/00

Abstract: Recombinant viruses, such as adeno-associated virus (rAAV) or lentivirus, for the treatment of glycogen storage disease type lb (GSD-Ib) are described. The recombinant viruses use either the human glucose-6-phosphatase (G6PC) promoter/enhancer (GPE) or the minimal human G6PT promoter/enhancer (miGT) to drive expression of human glucose-6-phosphate transporter (G6PT). The disclosed vectors are capable of delivering the G6PT transgene to the liver and correcting metabolic abnormalities in a murine model of GSD-Ib. The recombinant virus-treated mice maintained glucose homeostasis, tolerated a long fast, and did not elicit anti-G6PT antibodies. Methods of treating a subject diagnosed with GSD-Ib using the recombinant viruses is further described.